These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38809542)

  • 1. The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration.
    Karloski E; Dudley B; Diergaarde B; Blanco A; Everett JN; Levinson E; Rangarajan T; Stanich PP; Childers K; Brown S; Drogan C; Cavestro GM; Gordon K; Singh A; Simeone DM; Reich H; Kastrinos F; Zakalik D; Hampel H; Pearlman R; Gordon OK; Kupfer SS; Puzzono M; Zuppardo RA; Brand RE
    Cancer; 2024 Oct; 130(19):3297-3304. PubMed ID: 38809542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EUS-based Pancreatic Cancer Surveillance in
    Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study.
    Furniss CS; Yurgelun MB; Ukaegbu C; Constantinou PE; Lafferty CC; Talcove-Berko ER; Schwartz AN; Stopfer JE; Underhill-Blazey M; Kenner B; Nelson SH; Okumura S; Law S; Zhou AY; Coffin TB; Rodriguez NJ; Uno H; Ocean AJ; McAllister F; Lowy AM; Lippman SM; Klein AP; Madlensky L; Petersen GM; Garber JE; Goggins MG; Maitra A; Syngal S
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1021-1032. PubMed ID: 34625409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
    Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
    Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
    Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
    JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
    Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
    Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma.
    Ryu KH; Park S; Chun JW; Cho E; Choi J; Lee DE; Shim H; Kim YH; Han SS; Park SJ; Woo SM; Kong SY
    Cancer Res Treat; 2023 Oct; 55(4):1303-1312. PubMed ID: 37024097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.
    Abe T; Blackford AL; Tamura K; Ford M; McCormick P; Chuidian M; Almario JA; Borges M; Lennon AM; Shin EJ; Klein AP; Hruban RH; Canto MI; Goggins M
    J Clin Oncol; 2019 May; 37(13):1070-1080. PubMed ID: 30883245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
    Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
    Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk Genes.
    Gardiner A; Kidd J; Elias MC; Young K; Mabey B; Taherian N; Cummings S; Malafa M; Rosenthal E; Permuth JB
    J Natl Cancer Inst; 2022 Jul; 114(7):996-1002. PubMed ID: 35445726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O
    Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.
    Peters MLB; Eckel A; Lietz A; Seguin C; Mueller P; Hur C; Pandharipande PV
    Pancreatology; 2022 Sep; 22(6):760-769. PubMed ID: 35752568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history.
    Chaffee KG; Oberg AL; McWilliams RR; Majithia N; Allen BA; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Petersen GM
    Genet Med; 2018 Jan; 20(1):119-127. PubMed ID: 28726808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
    Power R; Leavy C; Nolan C; White N; Clarke R; Cadoo KA; Gallagher DJ; Lowery MA
    Fam Cancer; 2021 Apr; 20(2):97-101. PubMed ID: 32918181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Novel Protocol for Germline Testing in Pancreatic Cancer.
    McDonald HG; Kennedy A; Solomon AL; Williams CM; Reagan AM; Cassim E; Harper M; Burke E; Armstrong T; Gosky M; Cavnar M; Pandalai PK; Barry-Hundeyin M; Patel R; Nutalapati S; Moss J; Hull PC; Kolesar J; Pickarski JC; Kim J
    Ann Surg Oncol; 2024 Nov; 31(12):7705-7712. PubMed ID: 39133448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore.
    Zhang Z; Ishak NDB; Que FVF; Chua ZY; Chan SH; Chiang J; Yie JNY
    Hered Cancer Clin Pract; 2023 Apr; 21(1):5. PubMed ID: 37046302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers.
    Lee J; Ham JY; Park HY; Jung JH; Kim WW; Kang B; Chae YS; Lee SJ; Lee IH; Lee NY
    Sci Rep; 2022 Feb; 12(1):1842. PubMed ID: 35115620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.
    Hu C; Hart SN; Bamlet WR; Moore RM; Nandakumar K; Eckloff BW; Lee YK; Petersen GM; McWilliams RR; Couch FJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):207-11. PubMed ID: 26483394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.
    Rainone M; Singh I; Salo-Mullen EE; Stadler ZK; O'Reilly EM
    JAMA Oncol; 2020 May; 6(5):764-771. PubMed ID: 32053139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.